[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model

       

Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)

                      

Home Up vivoPharm Search Employment Feedback

Up in vitro Testing in vivo Testing ADME Tox

 

Subcutaneous
Orthotopic
Syngeneic
Angiogenesis

vivoPharmTM offers a Palette of Tumour Models  in Rodents

Our service is specialised to offer a combination of different tumour models to maximise clinical predictability. Our systems are adjusted to guarantee optimised readout in compound screening, validation and profiling. Using  standard SubQ screening models in combination with orthotopic and customised target-driven tumour models we will improved the efficiency of compound development. vivoPharm will assist you in experimental design in accordance to your needs. Furthermore,  we offer highly specialised target-driven tumour models and in particular a NeuT-driven syngeneic breast cancer model.

Subcutaneous Human Xenografts in BALB/c nu/nu mice

Orthotopic Human Xenografts in BALB/c nu/nu mice

NeuT-driven Syngeneic Breast Cancer Model in BALB/c mice

Syngeneic rat tumour models

Customised Syngeneic and/or Transgenic Models


 


   

Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003